Clinical Summarization & Chart Review
R

Regard

Regard reviews the entire electronic health record and recommends diagnoses to the clinician at the point of care, then generates the note around them. Founded 2017, based in Los Angeles and New York City. The company frames this as a diagnosis problem rather than a documentation problem: its stated premise is that physicians see roughly 3 percent of the data in a chart, and its diagnostic intelligence layer reviews the rest and surfaces conditions with the supporting chart evidence attached. Four modules run off the same engine: Clinical Notes, Mid Revenue Cycle, HCC Capture and Screening. In July 2025 the company added Proactive Documentation, combining chart data with ambient conversation from the room, plus an agent named Max, and described the platform as expanding from a hospitalist tool to system wide coverage. Named health system customers include Sentara Health, WakeMed, Penn Highlands Healthcare, Kettering Health, Main Line Health, FirstHealth, Westchester Medical Center, UAMS, Eisenhower Health and Torrance Memorial. Sentara reports a 17 percent increase in CC and MCC capture alongside a 4x return per user. The company reports 12,993,284 recommended diagnoses accepted by clinicians, and publishes site level figures including 50 million dollars in revenue earned at an Arizona health system, 9.3 million dollars in denials prevented at a North Carolina system and a 20 percent reduction in queries at a Pennsylvania system. Two things a buyer should weigh. First, Regard holds a regulatory artifact that is rare in this category and independently verifiable: an ONC Health IT Module certification, number 15.04.04.3192.Rega.01.00.0.240502, certified 2 May 2024 against 2015 Cures Update criteria covering electronic health information export, authentication and related privacy and security criteria. That is neither FDA clearance nor a HIPAA attestation, and no device authorisation or published clinical decision support exemption analysis was located for a product whose core function is recommending diagnoses. Second, every headline outcome the company publishes is financial or operational. None of them measures whether the recommended diagnoses were correct, and the acceptance figure is published as a count of accepted recommendations without the number recommended, so an acceptance rate cannot be derived from it.

Last VerifiedJuly 24, 2026
Compare Regard with other vendors
Founded
2017
Headquarters
Los Angeles and New York City, US
Website
regard.com
Categories
clinical-summarization, clinical-decision-support
Assessment

Capability Axes

AI Capability
AI Centrality
A
Vendor Published

The diagnostic engine is the product, not a feature attached to a platform the company already sold. Regard describes a proprietary diagnostic intelligence layer that ingests and maps millions of chart data points to clinical concepts and recommends diagnoses with supporting evidence, and every one of its four modules runs off that same engine. Nothing here is an EHR bundle or a workflow wrapper carrying someone else's intelligence.

Autonomy and Oversight Model
B
Vendor Published

The human gate is structural rather than asserted. Regard recommends and the clinician accepts or declines, and the company's own headline metric is the count of recommendations accepted by clinicians, which makes acceptance the unit of account. Recommendations arrive with the supporting chart evidence attached, and a customer quote on the HCC module describes knowing where a condition can be found in the chart and how it is supported. That is verification made checkable at the point of decision, the same property Abridge earns credit for with Linked Evidence, applied to a diagnosis rather than to note text. Held at B on the published denominator standard: 12,993,284 accepted is a numerator with no denominator, so the acceptance rate cannot be derived, and no confidence threshold, routing rule or abstention behaviour is published. Ask what fraction of recommendations clinicians decline, and what the product does when the chart evidence is weak.

Model and Technology Transparency
C
Vendor Published

The algorithms are described only as proprietary and clinically validated. No model stack, no accuracy figure, no model card, no validation publication and no error taxonomy was located. For the category's defining question this is the gap that matters: a product that reads the whole chart is judged on what it fails to surface, and no omission rate or false negative measure is published. The company does state that recommendations carry the chart evidence that supports them, which is a meaningful output level disclosure and is graded on the autonomy axis rather than here.

Clinical and Operational Evidence
B
Vendor Published

Well above the tail and short of independent. Multiple named health systems with named clinical executives on record and quantified site level deltas: Sentara Health at a 17 percent increase in CC and MCC capture with a 4x return per user, an appeals win rate reported moving from 20 to 80 percent, 9.3 million dollars in denials prevented at a North Carolina system, a 20 percent query reduction at a Pennsylvania system, and an earlier Torrance Memorial case study reporting 2 million dollars in annual revenue and 20 percent documentation time saved. That is measured operational outcome at named sites, not deployment volume standing in for evidence. Held at B because it is entirely vendor run and vendor published with no peer reviewed study located, and because the seller chose outcomes that are financial and throughput rather than diagnostic. Nothing published establishes the correctness of the recommendations themselves.

AI Safety and PHI Stewardship
C
Vendor Published

The grade describes the public disclosure surface, not conduct. Regard ingests the entire medical record, and the privacy policy published at regard.com is unedited template boilerplate: every section is prefixed with the words suggested text and the content concerns blog comments, Gravatar, cookies and image location data. It contains no provision on protected health information, retention of ingested chart data, training use or de identification. Nothing here establishes mishandling, and it should not be read that way. Enterprise health system agreements govern PHI through the business associate agreement and the security review, not through a website policy, and Regard is live at named academic and multi hospital systems that run those reviews. What it does establish is that the public artifact answers none of these questions and is unmaintained. Three items to obtain in writing: how long ingested chart data is retained, whether customer data is used to train or improve models, and the de identification posture for anything used beyond the treating encounter.

Regulatory and Compliance
HIPAA and BAA Posture
Not rated

No HIPAA compliance statement and no business associate agreement terms were located on any retrieved surface. A BAA certainly exists given the named health system deployments, but the index grades what is disclosed and nothing is. Note the distinction that this record turns on more than once: the ONC Health IT certification covers privacy and security criteria under a different framework and is not a HIPAA attestation. Do not let one stand in for the other.

Security Certifications and Trust Center
B
Regulatory Filing

Stronger than most of this index and short of what a health system security review asks for. Regard's ONC Health IT Module certification covers privacy and security criteria certified for the company itself by an ONC Authorized Certification Body, and the certification number 15.04.04.3192.Rega.01.00.0.240502 is publicly verifiable in the federal Certified Health IT Product List. That is a materially better artifact than the supplier certification language this index tracks as a watchlist, because it names the criteria, names the certifying body and can be looked up by the buyer. It also lists ISO 9001 as its quality management standard. Held at B because no SOC 2 Type II, no ISO 27001 and no trust centre was located, and because the multi factor authentication criterion is satisfied by relying on the EHR's own SMART on FHIR authentication rather than by a control Regard owns.

FDA and Regulatory Status
C
Regulatory Filing

A real regulatory credential exists and it is the wrong framework for the risk the product carries. The ONC Health IT Module certification, dated 2 May 2024 against 2015 Cures Update criteria, covers electronic health information export, authentication and related privacy and security criteria. It is an interoperability and security certification, and its own mandatory disclosure states it does not represent an endorsement by the Department of Health and Human Services. It is not FDA clearance. No device authorisation was located, and no published clinical decision support exemption analysis was located either, for a product whose core function is recommending diagnoses. Regard's design points toward the exemption criteria, since recommendations are evidence linked to the chart and a clinician can independently review the basis, but that analysis should be documented by the vendor rather than inferred by the buyer. Worth noting without drawing a conclusion from it: the certified criteria list does not include the Decision Support Interventions criterion. Ask which framework the company believes governs the diagnostic recommendation and to see the reasoning.

AI Governance and Bias Disclosure
C
Vendor Published

The grade describes incentive structure and disclosure, not wrongdoing, and the legitimate argument belongs in the same paragraph. Undocumented comorbidities are a genuine patient safety problem, the conditions named as examples are malnutrition, sepsis and hypertension, the physician remains the decision maker and signs, and every recommendation carries the chart evidence supporting it so a clinician can check whether the condition is actually present. The company positions itself against query driven capture with the line about earning revenue through better care rather than queries. Against that: the commercial pitch is dominated by revenue, the product ships a dedicated Mid Revenue Cycle module and an HCC Capture module, and the company's own impact calculator states that its recommended diagnoses lead to an upgraded MS DRG for 1.5 to 3 percent of encounters seen and that clients see reduced automated denials protecting a further 1 to 10 percent of charts with upgraded DRGs. Risk adjustment and severity capture are among the most litigated areas of United States healthcare compliance, and this index has graded milder versions of the same gradient down. Separately, no fairness, subgroup or accent disclosure of any kind was located.

Integration and Deployment
EHR and Interoperability Depth
A
Regulatory Filing

The strongest interoperability evidence in this category so far, because it is certified rather than claimed. Regard is a certified ONC Health IT Module implementing FHIR single patient and bulk electronic health information export, and it embeds in the EHR through SMART on FHIR, which is also what supplies its authentication. It describes deep data ingestion mapping millions of data points to clinical concepts, and it runs inside the chart at multiple large multi hospital systems. One gap named for the buyer: the company does not enumerate which EHR vendors are supported, so an organisation outside the major install bases should confirm its own system directly rather than infer it from the customer list.

Deployment Model and Data Residency
C
Vendor Published

The ONC mandatory disclosure names the certified product as Regard SaaS Solution v.1, which establishes a single hosted delivery model and no on premise option. Beyond that nothing is published: no hosting provider, no region, no data residency commitment and no customer choice over where ingested chart data is processed. For a product that ingests the entire record this is the open question, and it is the axis where this category will separate the same way the ambient lane did.

Commercial
Commercial Transparency
Not rated

No public pricing of any kind. Every route ends at a demo request. Not Rated is the house convention for absent pricing rather than a low grade, per the Abridge precedent. Worth distinguishing from pricing: Regard does publish a detailed return on investment calculator with its assumptions stated, including per query and per note time inputs and national coding benchmarks. That is transparency about claimed value, not about what the product costs, and the two should not be confused when comparing vendors on this axis.

Setting and Specialty Coverage
B
Vendor Published

Inpatient first and broadening. The product began as a hospitalist tool and the outcome measures it leads with, CC and MCC capture and MS DRG movement, are acute inpatient instruments. Coverage has since been described as system wide across all specialties, and the HCC Capture and Screening modules reach into population and ambulatory work. Graded B rather than A because the all specialties claim is asserted rather than demonstrated through specialty specific behaviour: no equivalent of the instrument level depth this index credits elsewhere, such as body mapped lesion documentation or paediatric growth charting, was located.

Commercial

Pricing

Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.

Entry Price Pricing Basis BAA Tier Implementation Source
Not published
Undisclosed. Enterprise health system agreement, sold per user based on the vendor's own return per user framing. Not published Not published. A Sentara executive described implementation as unusually simple relative to other health IT deployments, but no fee structure is stated either way. Vendor Published

Regard publishes no price, no tier and no pricing mechanism, and every commercial path terminates in a demo request. Commercial transparency is therefore Not Rated rather than graded down, per the house convention. What the company does publish instead is a return on investment model with its assumptions exposed, which is unusual and worth reading before a negotiation because it reveals how the vendor expects value to be counted. Its stated inputs include an average of 10 minutes per note, 20 minutes of physician time per clinical documentation improvement query, 60 minutes of CDI team time per query, a national benchmark that 20 to 30 percent of charts are reviewed and queried, an upgraded MS DRG on 1.5 to 3 percent of encounters seen, and a further 1 to 10 percent of charts with upgraded DRGs protected from automated denials. A buyer should note that this model prices the product against coding and denial outcomes, and should establish in writing whether any component of the fee varies with coding intensity, severity capture or collections rather than with users, volume or time saved. Non contingent pricing is a governance positive this index credits, and contingent pricing is not disqualifying but must be disclosed.

AI Health Index

An independent reference for evaluating AI vendors in healthcare. No vendor pays for inclusion, placement, or rating.

Index Status
Last index update
July 24, 2026
The AI Health Index is an editorial reference, not a regulatory body. Vendor data is verified against published sources and public regulatory filings. Figures labeled “Estimated” have not been confirmed by the vendor. See the Methodology page for evaluation standards and limitations.
© 2026 AI Health Index
3801 N Capital of Texas Hwy, Ste E240 · Austin, TX 78746